The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) announced this morning that the company has launched plans to develop a global product development and distribution division focused on the cannabinoid beverage industry.
The Organic Green Dutchman will be investing $55 million into the construction of a 40,000 sq. ft. R&D facility which will include ample space for product development and manufacturing. The company’s property will be dedicated to create proprietary cannabinoid infused beverages. The company plans to work collaborate with some of the top established beverage companies involved in the sector.
The new beverage division will utilize the company’s combined experience involved in the beverage industry to provide a clear path for new division to seek direct investments, strategic joint ventures and other suitable partnerships. The Green Organic Dutchman will be developing industry leading brands that contain organic ingredients.
Csaba Reider, TGOD President, gave this statement in the press release:
“TGOD will utilize state-of-the-art R&D facilities, intellectual property and a leadership team with more than 125 years of CPG beverage experience. We will create unique, healthy and organic products for the recreational and medicinal markets. We have the best access to capital, organic production capabilities and R&D resources in the world.”
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…